Lilly's Oral GLP-1, Orforglipron, Demonstrated Meaningful Weight Loss and Cardiometabolic Improvements in Complete ATTAIN-1 Results Published in The New England Journal of Medicine
Shortness of Breath: Severe Melaena can cause shortness of breath due to the reduced oxygen-carrying capacity of the blood
Additionally, several key clinical trial readouts delivered compelling data across multiple indications, for example (see Figure 1): Semaglutide : STEP-HFpEF (functional benefits in HFpEF), STEP-9 (pain reduction in knee osteoarthritis), STEP-10 (reversion to normoglycaemia in pre-diabetic, obese patients), ESSENCE (resolution of MASH, improvement in fibrosis) Tirzepatide : SUMMIT (risk reduction in HFpEF outcomes
L., Bave, U., Alm, G
Like all drugs, GLP-1s have side effects, including commonly reported gastrointestinal issues and, in rare cases, more serious complications such as pancreatitis